Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for psoriasis: oral drug shows promise in chinese trial

NCT ID NCT06122649

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug apremilast (Otezla) in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either apremilast or a placebo pill twice daily for 16 weeks. The main goal was to see if more people on apremilast achieved at least a 75% improvement in their psoriasis skin symptoms compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
apremilast (Otezla)
What this could lead to
If successful, this could provide a new oral treatment option for Chinese patients with moderate to severe plaque psoriasis, helping clear skin and reduce itching.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. Apremilast can cause side effects like nausea, diarrhea, and headache. It controls symptoms but does not cure psoriasis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

203 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Chinese participants aged ≥18. * Diagnosis of chronic, stable moderate to severe plaque PsO for ≥ 12 months before screening. The participant must have sPGA score ≥ 3, PASI score ≥ 12, and BSA involvement ≥ 10% at both screening and baseline (week 0). * Participant is a candidate for phototherapy and/or systemic therapy. Exclusion Criteria * Psoriasis flare within 4 weeks of screening. * Evidence of skin conditions that would interfere with evaluations of the effect of study medication on psoriasis. * Prior medical history of suicide attempt at any time in the participant's lifetime before screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years. * Participant has a malignancy or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years. * Active tuberculosis or a history of incompletely treated tuberculosis. * History of human immunodeficiency virus (HIV) infection. * Prior treatment with apremilast. * Female participants of childbearing potential unwilling to use protocol specified method of contraception. * Female participants who are breastfeeding or who plan to breastfeed. * Female participants planning to become pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • Changshu No2 Peoples Hospital

    Suzhou, Jiangsu, 215006, China

  • Chengdu Second Peoples Hospital

    Chengdu, Sichuan, 610017, China

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, 330000, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, 510091, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, 750003, China

  • Nanyang First Peoples Hospital

    Nanyang, Henan, 473002, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • Peoples Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, 830001, China

  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

  • Shandong Provincial Hospital For Skin Diseases,Shandong First Medical University

    Jinan, Shandong, 830001, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, 200443, China

  • Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350000, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Sichuan, 400010, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

  • Wuxi Peoples Hospital

    Wuxi, Jiangsu, 241023, China

  • Yichang Central Peoples Hospital

    Yichang, Hubei, 443003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.